{"id":9576,"date":"2022-10-04T22:55:06","date_gmt":"2022-10-04T22:55:06","guid":{"rendered":"https:\/\/ultimatehealthreport.com\/cbd-for-pain-what-does-the-science-say\/"},"modified":"2022-10-04T22:55:06","modified_gmt":"2022-10-04T22:55:06","slug":"cbd-for-pain-what-does-the-science-say","status":"publish","type":"post","link":"https:\/\/ultimatehealthreport.com\/cbd-for-pain-what-does-the-science-say\/","title":{"rendered":"CBD for Pain: What Does the Science Say?"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div property=\"content:encoded\">\n<p><em>Excerpted from <span class=\"caps\">CBD<\/span>: What Does the Science Say? by Linda A. Parker, Erin M. Rock, and Raphael Mechoulam, published by <span class=\"caps\">MIT<\/span> Press (2022, 309 pp.).<\/em><\/p>\n<p><div class=\"image-autosize image-align-none\"><\/div>\n<p>A large proportion of medicinal cannabis patients are using cannabis to treat pain syndromes, particularly for chronic pain alleviation. Cannabis use for unmanageable pain has been shown to reduce the dose of opiates required to achieve pain control, suggesting opioid-sparing effects. Although no published clinical trials have clearly demonstrated this opioid-sparing effect with <span class=\"caps\">CBD<\/span> alone, according to www.clinicaltrials.gov, registered clinical trials are investigating the interaction of <span class=\"caps\">CBD<\/span> and morphine effects on pain sensitivity (<span class=\"caps\">NCT04040442<\/span>) and abuse liability (<span class=\"caps\">NCT03679949<\/span>).<\/p>\n<p>Animal models suggest that <span class=\"caps\">CBD<\/span> is generally ineffective in reducing acute pain when administered systematically, but this may be because insufficient amounts of <span class=\"caps\">CBD<\/span> are reaching the brain to produce an analgesic effect. When <span class=\"caps\">CBD<\/span> is combined with <span class=\"caps\">THC<\/span> or morphine, it can potentiate the analgesic effects of these compounds to relieve acute pain, and analogs of <span class=\"caps\">CBD<\/span> also seem to have analgesic effects in acute pain models in animals.<\/p>\n<p>In animal models of neuropathic pain, <span class=\"caps\">CBD<\/span> is effective in preventing the development of certain types of chemotherapy- and diabetes-induced pain, as well as the treatment of already established chemotherapy-, spinal cord injury-, or post-operative-induced neuropathic pain. Indeed, a clinical study with topical <span class=\"caps\">CBD<\/span> improved pain ratings in neuropathic pain patients. Nabiximols [an oromucosal tincture with 2.7 mg <span class=\"caps\">THC<\/span> and 2.5 mg <span class=\"caps\">CBD<\/span> per spray] has also been shown to reduce pain and allodynia in neuropathic pain patients, with improvements maintained for an entire year.<\/p>\n<aside class=\"pull-right\">\n<p>When <span class=\"caps\">CBD<\/span> is combined with <span class=\"caps\">THC<\/span> or morphine, it can potentiate the analgesic effects of these compounds to relieve acute pain.<\/p>\n<\/aside>\n<p>In animal models, when administered prior to or following the initiation of inflammation or arthritis, <span class=\"caps\">CBD<\/span> can abolish neuropathic pain symptoms and reduce the associated swelling. Nabiximols (marketed as Sativex) has also been shown to reduce pain in rheumatoid arthritis patients who were unresponsive to standard treatments. These findings suggest that <span class=\"caps\">CBD<\/span> may be an adjunct treatment to investigate in inflammatory pain conditions such as arthritis.<\/p>\n<p><span class=\"caps\">CBD<\/span>\u2019s anti-inflammatory effects have also been demonstrated in animal models of brain injury due to interrupted blood flow to the brain. <span class=\"caps\">CBD<\/span> treatment within eighteen hours can reduce brain cell damage and inflammation and restore brain activity. In animal and cellular models of gastrointestinal tract inflammation, <span class=\"caps\">CBD<\/span> has anti-inflammatory effects and restores the integrity of the gut lining. A handful of human studies also suggest that <span class=\"caps\">CBD<\/span> may improve inflammatory bowel disease symptoms and restore intestinal integrity, but further research is needed.<\/p>\n<p>Sublingual spray-delivered <span class=\"caps\">CBD<\/span> alone (as well as nabiximols) reduced pain and spasticity scores in multiple sclerosis patients, and topical application of <span class=\"caps\">CBD<\/span> relieved myofascial pain and neuropathic pain. To date, nearly fifty clinical trials registered at www.clinicaltrials.gov are investigating the ability of <span class=\"caps\">CBD<\/span> (alone or in combination with <span class=\"caps\">THC<\/span>) to reduce pain associated with conditions such as tooth extractions, chronic back pain, postsurgical pain, diabetic neuropathy, and cancer pain. These important properly controlled randomized clinical trials will help to better understand the potential analgesic properties of <span class=\"caps\">CBD<\/span>.<\/p>\n<p><em>About the authors of <span class=\"caps\">CBD<\/span>: What Does the Science Say? published by <span class=\"caps\">MIT<\/span> Press: Linda Parker is Professor Emeritus in the Psychology and Collaborative Neuroscience Program at the University of Guelph in Ontario and author of Cannabinoids and the Brain (<span class=\"caps\">MIT<\/span> Press). Erin M. Rock is a Postdoctoral Fellow and Adjunct Faculty member in the Psychology and Collaborative Neuroscience Program at the University of Guelph. Raphael Mechoulam, often called \u201cthe father of cannabis research,\u201d is the Lionel Jacobson Professor of Medicinal Chemistry at Hebrew University in Jerusalem and winner of the 2019 Harvey Prize for outstanding contributions to science and technology.<\/em><\/p>\n<p>Buy on Amazon<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.projectcbd.org\/cbd-pain-what-does-science-say\" target=\"_blank\" rel=\"noopener\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Excerpted from CBD: What Does the Science Say? by Linda A. Parker, Erin M. Rock, and Raphael Mechoulam, published by MIT Press (2022, 309 pp.). [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9577,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/posts\/9576"}],"collection":[{"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/comments?post=9576"}],"version-history":[{"count":0,"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/posts\/9576\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/media\/9577"}],"wp:attachment":[{"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/media?parent=9576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/categories?post=9576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ultimatehealthreport.com\/wp-json\/wp\/v2\/tags?post=9576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}